Skip to Content
Merck

V-016

Nicotinamide (Vitamin B3) solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Synonym(s):

Nicotinamide, Vitamin B3, Niacinamide, Nicotinic acid amide, Pyridine-3-carboxylic acid amide, Vitamin PP

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C6H6N2O
CAS Number:
98-92-0
Molecular Weight:
122.12
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329828959
EC Number:
200-659-6
Beilstein/REAXYS Number:
383619
MDL number:
MFCD00006395

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

DFPAKSUCGFBDDF-UHFFFAOYSA-N

InChI

1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

SMILES string

NC(=O)c1cccnc1

grade

certified reference material

Quality Level

300

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

format

single component solution

storage temp.

−20°C

Related Categories

General description

Nicotinamide is also known as niacinamide or nicotinic acid amide. It is the water-soluble form of Vitamin B3 found in plant and animal foods and mostly used as a dietary supplement.

Application

This certified solution standard is suitable for a variety of testing applications including quality control testing by HPLC for pharmaceutical preparations or dietary supplements.
Nicotinamide may be used as an analytical reference standard for the determination of the analyte in energy drinks by planar chromatography-multiple detection with confirmation by electrospray ionization mass spectrometry and in pharmaceutical formulations, by UV-visible spectrophotometry and multivariate analysis.

Biochem/physiol Actions

Nicotinamide is an amide derivative of vitamin B3 and a PARP inhibitor

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Simultaneous determination of riboflavin, pyridoxine, nicotinamide, caffeine and taurine in energy drinks by planar chromatography-multiple detection with confirmation by electrospray ionization mass spectrometry
Aranda M and Morlock G
Journal of Chromatography A, 1131(1-2), 253-260 (2006)
Simultaneous determination and classification of riboflavin, thiamine, nicotinamide and pyridoxine in pharmaceutical formulations, by UV-visible spectrophotometry and multivariate analysis
Lopez-de-Alba LP, et al.
Journal of the Brazilian Chemical Society, 17(4), 715-722 (2006)
Ning Jia et al.
Anticancer research, 33(6), 2797-2800 (2013-06-12)
Post-transplant hepatocellular carcinoma recurrence has been reported to be between 15-18% and is higher among patients with high-risk features (bilobar tumor, macrovascular invasion, or multifocality). There are no known treatments which reduce risk of recurrence post-transplant. Sorafenib is currently approved
New options for second-line therapy of advanced renal cancer.
Axel Bex
The Lancet. Oncology, 14(6), 450-451 (2013-04-20)
Robert J Motzer et al.
The Lancet. Oncology, 14(6), 552-562 (2013-04-20)
In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib had a longer progression-free survival (PFS). Here, we report overall survival and updated efficacy, quality
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service